Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528242 | 0.98 | GBA2 (0.39) | GBA2CYP2C19CES1 | |
| SCHEMBL2529656 | 0.98 | GBA2 (0.39) | GBA2CYP2C19CES1 | |
| SCHEMBL2531069 | 0.92 | CYP2C19 (0.35) | GBA2CYP2C19 | |
| SCHEMBL25939791 | 0.87 | GBA2 (0.42) | GBA2CYP2C19CES1 | |
| SCHEMBL2525969 | 0.81 | — | — | |
| SCHEMBL1244600 | 0.81 | GBA2 (0.38) | GBA2CYP2C19CES1 | |
| SCHEMBL26016323 | 0.78 | GBA2 (0.37) | GBA2CYP2C19CES1 | |
| SCHEMBL26016322 | 0.78 | GBA2 (0.37) | GBA2CYP2C19CES1 | |
| SCHEMBL26016324 | 0.78 | GBA2 (0.37) | GBA2CYP2C19CES1 | |
| SCHEMBL5961078 | 0.78 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-9670232-B2 | Molecular precursor compounds for zinc-group 13 mixed oxide materials | TRANSTRON SOLUTIONS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3102541-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR INDIUM GALLIUM ZINC OXIDE MATERIALS | TRANSTRON SOLUTIONS LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9455142-B2 | Molecular precursor compounds for ABIGZO zinc-group 13 mixed oxide materials | TRANSTRON SOLUTIONS LLC (US) | 2016-09-27 | — | — | US | disclosed |
| US-9404002-B2 | Molecular precursor compounds for indium gallium zinc oxide materials | TRANSTRON SOLUTIONS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150218190-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ZINC-GROUP 13 MIXED OXIDE MATERIALS | PRECURSOR ENERGETICS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150221506-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABIGZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | PRECURSOR ENERGETICS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150221772-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABIZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | PRECURSOR ENERGETICS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218400-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR INDIUM GALLIUM ZINC OXIDE MATERIALS | PRECURSOR ENERGETICS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150221771-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABGZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | PRECURSOR ENERGETICS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0649423-B1 | PROCESS FOR PREPARING 1,3-DIOXOLANE DERIVATIVES | SYNTEX INC (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5274108-A | Process for preparing 1,3-dioxolane derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5208331-A | Process for preparing 1,3-dioxolane derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218400-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR INDIUM GALLIUM ZINC OXIDE MATERIALS | IKZF3, ZFR, IGSF11 | GBA2 3442/4885CYP2C19 1188/4885CES1 4760/4885 |
| US-20150221506-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABIGZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | AOC3, ZRANB2, AOC2 | GBA2 4326/4885CYP2C19 90/4885CES1 4684/4885 |
| US-20150221772-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABIZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | IKZF3, ZRANB2, ZFR | GBA2 4279/4885CYP2C19 242/4885CES1 4834/4885 |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | GBA2 3362/4885CYP2C19 4097/4885CES1 2088/4885 |
| US-20150221771-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ABGZO ZINC-GROUP 13 MIXED OXIDE MATERIALS | ZFR, IKZF3, SLC39A11 | GBA2 2400/4885CYP2C19 176/4885CES1 4811/4885 |
| US-20150218190-A1 | MOLECULAR PRECURSOR COMPOUNDS FOR ZINC-GROUP 13 MIXED OXIDE MATERIALS | ZFR, ZRANB2, IKZF3 | GBA2 3326/4885CYP2C19 77/4885CES1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.